Literature DB >> 18187690

Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia.

Young R Kim1, Maurits P A van Meer, Emiri Tejima, Yoshi Murata, Joseph B Mandeville, George Dai, De-Maw Chuang, Bruce R Rosen, Eng H Lo.   

Abstract

BACKGROUND AND
PURPOSE: The use of lithium as a neuroprotective agent has been demonstrated using various models in which improvements in infarct size, DNA damage, and neurological function were reported. We further investigated neurohemodynamic aspects of the treatment-associated recovery by assessing the therapeutic efficacy of delayed chronic lithium treatment using functional MRI.
METHODS: Ipsilesional functional MRI activations in the somatosensory cortex, acquired 2 weeks after the 90-minute transient middle cerebral artery occlusion, were compared between lithium- and saline-treated rats. Specifically, MRI signal changes based on blood oxygenation level dependence and functional cerebral blood volume responses were examined using electrical stimulation of forelimbs. Additional immunohistochemical assays were performed.
RESULTS: The ratio of ipsilesional to contralesional blood oxygenation level dependence response magnitudes significantly improved with lithium treatments. In contrast, the increase of the functional cerebral blood volume response magnitude ratio was not statistically significant. Nonetheless, the lithium treatment induced significant enhancements of total functional MRI activation (defined as a product of activation volume and response magnitude) for both blood oxygenation level dependence and functional cerebral blood volume methods. Increased cerebral blood volume in periinfarct tissues suggests a possible stroke-induced vascular transformation in both saline- and lithium-treated rats; however, other MRI-derived vascular parameters (vascular size index and microvascular volume) and immunohistochemical staining (CD31, glia fibrillary-associated protein, and matrix metalloproteinase-9) may imply that the neoformation of vasculature was differently affected by the lithium treatment.
CONCLUSIONS: The delayed chronic lithium treatment enhanced the blood oxygenation level dependence functional MRI response magnitude in the absence of neurological improvement and influenced vascular formation in poststroke animal models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187690      PMCID: PMC3712848          DOI: 10.1161/STROKEAHA.107.492215

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

Review 1.  Diffusion tensor imaging: concepts and applications.

Authors:  D Le Bihan; J F Mangin; C Poupon; C A Clark; S Pappata; N Molko; H Chabriat
Journal:  J Magn Reson Imaging       Date:  2001-04       Impact factor: 4.813

2.  MRI measurement of the temporal evolution of relative CMRO(2) during rat forepaw stimulation.

Authors:  J B Mandeville; J J Marota; C Ayata; M A Moskowitz; R M Weisskoff; B R Rosen
Journal:  Magn Reson Med       Date:  1999-11       Impact factor: 4.668

3.  Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model.

Authors:  S A Menzies; J T Hoff; A L Betz
Journal:  Neurosurgery       Date:  1992-07       Impact factor: 4.654

4.  Is all perfusion-weighted magnetic resonance imaging for stroke equal? The temporal evolution of multiple hemodynamic parameters after focal ischemia in rats correlated with evidence of infarction.

Authors:  G Zaharchuk; M Yamada; M Sasamata; B G Jenkins; M A Moskowitz; B R Rosen
Journal:  J Cereb Blood Flow Metab       Date:  2000-09       Impact factor: 6.200

5.  Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration.

Authors:  R V Bhat; J Shanley; M P Correll; W E Fieles; R A Keith; C W Scott; C M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival.

Authors:  Min-Huei Liang; De-Maw Chuang
Journal:  J Biol Chem       Date:  2006-12-05       Impact factor: 5.157

7.  Role of matrix metalloproteinases in delayed cortical responses after stroke.

Authors:  Bing-Qiao Zhao; Sophia Wang; Hahn-Young Kim; Hannah Storrie; Bruce R Rosen; David J Mooney; Xiaoying Wang; Eng H Lo
Journal:  Nat Med       Date:  2006-03-26       Impact factor: 53.440

8.  Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats.

Authors:  Jihong Xu; Annedore Scholz; Nicole Rösch; Annegret Blume; Thomas Unger; Reinhold Kreutz; Juraj Culman; Peter Gohlke
Journal:  J Hypertens       Date:  2005-12       Impact factor: 4.844

9.  Functional magnetic resonance imaging of reorganization in rat brain after stroke.

Authors:  R M Dijkhuizen; J Ren; J B Mandeville; O Wu; F M Ozdag; M A Moskowitz; B R Rosen; S P Finklestein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Measurements of BOLD/CBV ratio show altered fMRI hemodynamics during stroke recovery in rats.

Authors:  Young R Kim; In J Huang; Seong-Ryong Lee; Emiri Tejima; Joseph B Mandeville; Maurits P A van Meer; George Dai; Yong W Choi; Rick M Dijkhuizen; Eng H Lo; Bruce R Rosen
Journal:  J Cereb Blood Flow Metab       Date:  2005-07       Impact factor: 6.200

View more
  20 in total

1.  Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury.

Authors:  Yaqi Zhou; Xianqiu Zeng; Ge Li; Qiuhua Yang; Jiean Xu; Min Zhang; Xiaoxiao Mao; Yapeng Cao; Lina Wang; Yiming Xu; Yong Wang; Yu Zhang; Zhengshuang Xu; Chaodong Wu; Jiang-Fan Chen; Md Nasrul Hoda; Zhiping Liu; Mei Hong; Yuqing Huo
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

Review 2.  Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Authors:  Zhi-fei Wang; Emily Bame Fessler; De-Maw Chuang
Journal:  Acta Pharmacol Sin       Date:  2011-11-07       Impact factor: 6.150

Review 3.  Neuroprotective action of lithium in disorders of the central nervous system.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-06

Review 4.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

5.  Reduced microvascular volume and hemispherically deficient vasoreactivity to hypercapnia in acute ischemia: MRI study using permanent middle cerebral artery occlusion rat model.

Authors:  J Y Suh; Woo H Shim; Gyunggoo Cho; Xiang Fan; Seon J Kwon; Jeong K Kim; George Dai; Xiaoying Wang; Young R Kim
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-18       Impact factor: 6.200

6.  Differentiation of the brain vasculature: the answer came blowing by the Wnt.

Authors:  Stefan Liebner; Karl H Plate
Journal:  J Angiogenes Res       Date:  2010-01-14

Review 7.  Functional role of inorganic trace elements in angiogenesis part III: (Ti, Li, Ce, As, Hg, Va, Nb and Pb).

Authors:  Mohammad Ali Saghiri; Jafar Orangi; Armen Asatourian; Christine M Sorenson; Nader Sheibani
Journal:  Crit Rev Oncol Hematol       Date:  2015-10-20       Impact factor: 6.312

8.  Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes.

Authors:  Shuzhen Guo; Ken Arai; Monique F Stins; De-Maw Chuang; Eng H Lo
Journal:  Stroke       Date:  2008-10-30       Impact factor: 7.914

Review 9.  Molecular actions and clinical pharmacogenetics of lithium therapy.

Authors:  Adem Can; Thomas G Schulze; Todd D Gould
Journal:  Pharmacol Biochem Behav       Date:  2014-02-15       Impact factor: 3.533

Review 10.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.